GLSV co-finances Sandoz spin-off Nabriva GmbH
ABRI was originally founded in 2001 with the objective of discovering and developing new antibiotic compounds. With Sandoz's recent strategic re-orientation as the generics company within Novartis, it was decided to spin off ABRI and allow the late-preclinical stage company to develop outside of the Sandoz structure.
Nabriva will focus on the development of small molecule antibiotics for use in community and hospital infections. Nabriva has a strong pipeline of antibacterial drugs including three late preclinical projects and one product about to enter Phase 1 clinical trials. All the projects are based on families of small molecules with known antibiotic activity.
Organizations
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.